Urologia Internationalis **Research Article**

Urol Int 2021;105:969-985 DOI: 10.1159/000508171

Received: November 4, 2019 Accepted: April 16, 2020 Published online: September 14, 2021

A Meta-Analysis of Erectile Dysfunction and Alcohol Consumption

Shen Li^a Ju-Min Song^a Ke Zhang^b Chang-Le Zhang^c

^aDepartment of Medical Administration, The First Affiliated Hospital of Anhui Medical University, Hefei, China; ^bOffice of Party Committee, The First Affiliated Hospital of Anhui Medical University, Hefei, China; ^cDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Keywords

Alcohol consumption · Erectile dysfunction · Meta-analysis

Abstract

Purpose: The purpose of the study was to evaluate the association between alcohol consumption and risk of erectile dysfunction (ED). Methods: PubMed was searched for reports published before June 2019. Data were extracted and combined odds ratios (ORs) calculated with random-effects models. Results: Finally, 46 studies were included (216,461 participants). The results of our meta-analysis indicated that there was a significant association between regular alcohol consumption and ED (OR 0.89, 95% confidence interval [CI]: 0.81-0.97). There was no indication of publication bias (Eqger's test, p = 0.37). In the stratified analysis, the pooled OR of ED for light to moderate and high alcohol consumption was 0.82 (95% CI: 0.72-0.94) and 0.82 (95% CI: 0.67-1.00), respectively. No variable related to the source of heterogeneity was found in univariate and multivariate meta-regression analyses. A dose-response meta-analysis suggested that a nonlinear relationship between alcohol consumption and risk of ED was observed (p for nonlinearity <0.001). Conclusion: A J-shaped relationship between alcohol consumption and risk of ED was observed. Alcohol should be taken in

karger@karger.com www.karger.com/uin © 2021 S. Karger AG, Basel

moderate quantities in order to obtain the dual effect of disinhibition and relaxation. If taken chronically, it could provoke vascular damages. © 2021 S. Karger AG, Basel

Introduction

Erectile dysfunction (ED) has been one of the most common complaints among men with sexual health issues [1], accurately defined as the persistent inability to attain a satisfactory erection of the penis to permit satisfactory sexual intercourse [2]. It has been estimated that worldwide the prevalence of ED will be 322 million cases by the year 2025 [3]. It is evident that ED has become a measurable health disorder for men globally that requires medical and public health attention. Risk factors, including hypertension, diabetes mellitus, coronary artery diseases, and sociodemographic conditions, has been associated with ED [4]. It is of interest to look at the significant effect of alcohol consumption on improvement of erectile function.

Although drinking is often associated with men's sexual activity, the findings of studies examining alcohol's effects on men's ED remained inconsistent. Animal exDownloaded from http://karger.com/uin/article-pdf/105/11-12/969/3979696/000508171.pdf by guest on 21 May 2022



Correspondence to: Shen Li, ls831007@sina.com

periments show that chronic consumption of high doses of alcohol (Male Wistar rats, ethanol: 20% v/v, for 6 weeks) increases the expression of the catalytic subunits of the enzyme nicotinamide adenine dinucleotide phosphate oxidase, which is the main source of reactive oxygen species in the endothelium and vascular smooth muscle cells [5, 6]. Reactive oxygen species induce activation of mitogen-activated protein kinases and production of inflammatory cytokines [7]. Moreover, chronic alcohol consumption (Male Wistar rats, ethanol: 20% v/v, for 6 weeks) increases reactive oxygen species production in the corpus cavernosum, which may contribute to ED [7]. Some epidemiological studies have shown that chronic consumption of high doses of alcohol might exert a damaging effect on ED in general population [8, 9]. However, a few of articles were different from the results of above ones [10, 11], those shown that a high dose of alcohol was not associated with ED.

The light and moderate consumption of alcohol might produce a protective effect on ED in both diabetic men and in general population [12, 13], and partly, the beneficial effects of alcohol on erectile function might be due to the long-term benefits of alcohol on high-density lipoprotein cholesterol and other variables that increased the availability and activity of nitric oxide. Moreover, light to moderate alcohol consumption upregulates paraoxonase 1 expression and serum activity, whereas heavy alcohol consumption had the opposite effects in both animals and humans. Paraoxonase 1 can detoxify the homocysteine metabolism, which can pathologically cause toxic effects on the endothelium [14]. So it was fair to hypothesize that alcohol may demonstrate a J-shaped relationship with ED. Although there were 2 meta-analysis studies and they had summarized the relationship between alcohol consumption and ED, they included a limited number of references and did not demonstrate the threshold level of alcohol consumption exerting a damaging effect on ED. We therefore performed this metaanalysis of the available epidemiological evidence assessing the relationship between alcohol consumption and ED risk.

Materials and Methods

Search Strategy

Based on the hospital's limited biomedical database, PubMed was searched for reports published from inception to May 2019, with the keywords "alcohol," "ethanol," and "Erectile." The reference lists of identified publications (including reviews) were also searched to identify further pertinent studies.

Selection Criteria

All identified studies were independently reviewed by 2 investigators (S.L. and J.M.S.). Studies, if they had been reported in English, the exposure of interest was alcohol or ethanol, and the outcome of interest was ED, odds ratio (OR) or RR with 95% confidence interval (CI) were provided or data provided allowed their calculation, were included in the present meta-analysis. The largest study was preferred when data were duplicated. Animal studies, reviews, systematic reviews, meta-analyses, or studies without sufficient data were excluded before full-text assessment.

Data Extraction

Data were extracted independently from each study by 2 investigators (S.L. and J.M.S.). The first author's last name, year of publication, country/region, population sources, design type, definition, age, number of cases and sample size, level of alcohol consumption, OR or RR with 95% CI for each category of alcohol consumption, and details of adjustment for potential confounding factors were recorded.

Statistical Analysis

The Mantel-Haenszel method was used to calculate OR or RR and 95% CI, when studies were not provided. If the incidence of disease is low, RR is approximately equal to OR [15]. The combined effects were estimated by combined OR, which was calculated by combining logarithmic risk estimates, for random-effects models, weighted by the inverse variance method to evaluate the association between al-cohol consumption and ED risk. The I^2 statistic was used to assess heterogeneity between eligible studies. If $I^2 > 50\%$, the heterogeneity was considered to be statistically significant. To explore the source of heterogeneity, we operated meta-regression with covariables, such as region, population sources, definition of ED, adjusted and grade of ED. Subgroup analysis was further operated to assess the effects of the factors which had been identified by meta-regression. The potential publication bias was estimated by Egger's quantitative test.

The pooled dose-response relationship between alcohol consumption and ED risk was explored by a dose-response meta-analysis. Exposure data were converted into a uniform measurement (drinks/week). If alcohol consumption was reported in drinks/day, we multiplied the consumption by 7. When alcohol consumption was reported in g/day, the alcohol intake was converted into drinks/week assuming that 1 drink contains 12 g of alcohol [16]. The median or mean alcohol consumption was considered as the corresponding exposure dose. If the median or mean consumption was not reported, the midpoint between the upper and lower range was assigned in each category as the median consumption. When the lowest category was open-ended, its lower boundary was set to zero. When the highest category was unrestricted for alcohol consumption, the exposure dose was defined by the lower end value of the category multiplied by 1.2. A median intake of <14 drinks/ week was defined as light to moderate alcohol consumption; a median intake of \geq 14 drinks/week was defined as high consumption. Nondrinkers and <1 drink/week (concluding: socially, monthly, noncurrent, and abstains) were regarded as the reference group.

A restricted cubic spline model was estimated using generalized least square regression to assess the pooled dose-response relationship between alcohol consumption and ED risk. All statistical analyses were performed using Stata (version 12.0, StataCorp, College Station, TX, USA), statistical tests were 2-sided and used a significance level of p < 0.05.

| Author, reference | Country/ region | Population sources | Design type | Definition | Age, years | Sample size | Alcohol consumption | ORs (95% CI) | Adjustments |
|--------------------------|--------------------|-----------------------|-----------------|------------|-----------------|----------------|-------------------------|----------------------------|---|
| Song | Korea | Population- | Longitudinal | IIEF-5 | 20-69 | 006 | None | 1 | |
| é [/د] .ta | | based | | | | | Drinking | $1.640 \\ (1.183 - 2.273)$ | |
| Pozzi | Italy | Patients | Cross-sectional | IIEF-15 | <40 | 307 | None | 1 | Age, smoking history, physical activity, Charlson |
| et al. [¿č] | | | | | | | Drinking | 0.95 (0.43–2.13) | comorbidity, hypertension, beck s inventory for depression score, and International Prostate Symptom Score |
| Sanches | Brazil | Patients | Cross-sectional | IIEF-5 | 59.64±9.66 | 689 | None | 1 | Subjective penile size, comorbidity, satisfactory |
| et al. [52] | | | | | | | Drinking | 1.14 ($0.80-1.63$) | ejaculation tume, age, BML, objective penile size, sexual intercourse frequency, total testosterone, metabolic syndrome, systolic blood pressure ≥130 mm Hg, serum glucose, regular physical activity, tobacco consumption, abdominal circumference >102 cm, age of sexual initiation, masturbatory frequency, level of education, prostate volume, weight, diastolic blood pressure ≥85 mm Hg, cholesterol, total PSA, and estradiol |
| Boeri | Italy | Patients | Cross-sectional | IIEF-15 | 54.8±12.9 | 372 | None | 1 | Age, BMI, Charlson comorbidity index, Total |
| et al. [1c] . | | | | | | | Drinking | 1.11 (0.58–2.49) | testosterone, smoking, and prediabetes |
| Seid | Ethiopia | Diabetic | Cross-sectional | IIEF-5 | 43.39±14.7 | 249 | None | 1 | |
| et al. [50] ¹ | | patients | | | | | Drinking | 1.019 (0.561–1.850) | |
| Clemente | Brazil | Polydrug | Cross-sectional | IIEF-15 | 36.4 ± 11.9 | 102 | None | 1 | |
| et al. [49]* | | dependent sample | | | | | Drinking | 1.188 (0.457–3.087) | |
| Van Vo | Vietnam | Population- | Cross-sectional | IIEF-5 | 44.3 ± 8.7 | 746 | None | 1 | Age, occupation, religion, disease history, BMI, |
| et al. [48] ² | | Dased | | | | | Drinking | 1.82 (1.26–2.64) | anxiery, quairry or inte, consensuai sex with wire/ partner, and hours sleeping |
| Costa | Brazil | Chronic | Cross-sectional | IIEF-15 | 65.11±13.98 245 | 245 | Noncurrent | 1 | |
| et al. [40] | | kuniey uisease | | | | | Current alcohol user | 0.75 (0.35–1.60) | |

Table 1. Characteristics of studies included in the meta-analysis

Erectile Dysfunction and Alcohol Consumption

| Alcohol ORs (95% CI) Adjustments consumption | 1 | 1-199 g/day 0.892 sexual partners, smoking, drinking, education (0.877-1.000) levels, personal incomes, and medical history | 200–299 g/day 1.036 (0.846–1.266) | ≥300 g/day 1.185 (0.986-1.198) | e 1 | Drinking 1.084 (0.471–2.497) | Nondrinker 1 Age, BMI, duration of diabetes, current smoking, | Anypertension, dyslipidemia, coronary artery 0.39 disease, stroke, HbA1c, diabetic nephropathy, (0.23-0.66) diabetic retinopathy, and diabetic neuropathy | ≥60 g/day 0.69 (0.36-1.32) | 1 | Drinking 3.25 blockers, coronary insufficiency, and years of use (1.41–7.51) of alcohol | er l | Taking it 0.921 (0.655–1.296) | Age, year of survey, civil status, BMI, morbidity, (0.68–1.62) use of medication, exercise, and smoking | Monthly 1 | kly 1.09 (0.82-1.45) | |
|---|-----------------|---|--------------------------------------|-----------------------------------|-----------------|---------------------------------|---|---|-------------------------------|-----------------|---|-----------------|-----------------------------------|---|-----------|-------------------------|--|
| | 10 Socially | 1-19 | 200- | ≥300 | None | Drin | | <60 | 560 | None | Drin | Never | Taki | | Mon | Weekly | |
| ears Sample size | 5,210 | | | | 8.51 350 | | 0.0 340 | | | 54.09±13.17 305 | | 3.4 600 | | 15,112 | | | |
| Age, years | ≥40 | | | | 62.34±8.51 | | 57.0±10.0 | | | 54.09± | | 33.6±13.4 | | e ≥45 | | | |
| Definition | IIEF-5 | | | | IIEF-5 | | Sexual health | inventory for men score <8 | | IIEF-15 | | IIEF-5 | | Questionnaire ≥45 | | | |
| Design type | Cross-sectional | | | | Cross-sectional | | Cross-sectional | | | Cross-sectional | | Cross-sectional | | Cross-sectional | | | |
| Population sources | Population- | based | | | Patients | | iabetic | patients | | Hemodialysis | patients | Population- | based | Population- based | | | |
| Country/ region | China | | | | Turkey | | Japan | | | Brazil | | Nigeria | | Sweden | | | |
| Author, reference | Zhang | et al. [10] ^{1, 2} | | | Benli | et al. [46]¹ | Furukawa | et al. [11] ^{1, 2} | | Costa | et al. [45]* | Olugbenga- | Bello et al. [44] ¹ | Stranne et al. [43] ¹ | | | |

972

Table 1 (continued)

| Table 1 (continued) | ntinued) | | | | | | | | |
|--|--------------------|-----------------------|--------------------------|-------------------------------------|------------|----------------|------------------------|-------------------------|---|
| Author, reference | Country/ region | Population sources | Design type | Definition | Age, years | Sample size | Alcohol consumption | ORs (95% CI) | Adjustments |
| Weber | Australia | Population- | Cross-sectional | Questionnaire ≥45 | | 101,674 | 0 drinks/week | 1 | |
| et al. [9]* | | based | | | | | 15 drinks/week | 0.67 (0.64–0.70) | |
| | | | | | | | 610 drinks/week | 0.69 (0.66–0.71) | |
| | | | | | | | 1115 drinks/week | 0.68 (0.65–0.72) | |
| | | | | | | | 1620 drinks/week | 0.38 ($0.35-0.40$) | |
| | | | | | | | 2025 drinks/week | 0.69 (0.65 -0.74) | |
| | | | | | | | 2630 drinks/week | 0.71 (0.66–0.76) | |
| | | | | | | | >30 drinks/week | 0.78 (0.73–0.83) | |
| Araujo | USA | Population- | Prospective ³ | Questionnaire 40-70 | | 1,655 | <1 drink/day | 1 | |
| et al. [¿č] ² | | based | | | | | 1 drink/day | 0.650 (0.483–0.875) | |
| | | | | | | | 2+ drinks/day | 0.925 (0.674–1.269) | |
| Wu Iroll I | China | Population- | Cross-sectional | IIEF-5 | 20-79 | 2,686 | None | 1 | Age, high school graduation, physical activity, |
| et al. [42] ² | | Dased | | | | | Drinking | 0.96 (0.82-1.13) | obesity, nypertension, aysupidemia, alabetes, and smoking |
| Chao Chao | Taiwan | Military | Cross-sectional | IIEF-5 | 21.66±0.92 | 364 | None | 1 | BMI, testosterone, and smoking |
| et äl. [41] ⁻ | | examinations | | | | | Drinking | 4.67 (0.55–39.32) | |
| Christensen et al. [40] ^{1, 2} | Denmark | Population- based | Cross-sectional | Diagnostic and 16–97 statistical | | 91 | None | 1.97 (0.76–5.12) | Age, place of residence, educational level, post- secondary education, household income, |
| | | | | manual or mental | | | 1-7 drinks/week | 1 | difficulties paying bills last year, marital status, smoker status, and, except in analyses of waist |
| | | | | Disorders, 4th edition | | | 8–21 drinks/week | 1.90 (0.98–3.70) | circumference and BMI |
| | | | | | | | >21 drinks/week | 1.33 (0.56–3.15) | |
| | | | | | | | | | |

| Author, reference | Country/ region | Population sources | Design type | Definition | Age, years | Sample size | Alcohol consumption | ORs (95% CI) | Adjustments |
|--------------------------|--------------------|-----------------------|-----------------|---------------------|-----------------|----------------|------------------------|-------------------------|--|
| Jeong | Korea | Population- | Cross-sectional | Modified | 66.1 ± 6.8 | 203 | None | 1 | |
| et al. [39]* | | Dased | | C-1311 | | | Drinking | 0.875 (0.443-1.727) | |
| Holden | Australia | Population- | Cross-sectional | Questionnaire ≥40 | ≥ ≥40 | 4,991 | None | 1 | Age |
| et al. [38] ¹ | | based | | | | | ≤18 drinks/week | 0.7 (0.6–0.9) | |
| | | | | | | | >18 drinks/week | 1.1 (0.8-1.6) | |
| Stolic | Serbia | Hemodialysis | Cross-sectional | IIEF-5 | 54.51 ± 6.9 | 73 | None | 1 | |
| et al. [3/] [*] | | | | | | | Drinking | 6.462 (0.785–53.182) | |
| Lee | China | Population- | Cross-sectional | Questionnaire 20-70 | e 20-70 | 1,506 | Never drinker | 1 | Age of 5 years and smoking habit |
| et al. [30] | 1 | Dased | | | | | Current drinker | 1.54 (0.94–2.53) | |
| | | | | | | | ≤1 drink/week | 0.73 (0.21–2.55) | |
| | | | | | | | 2 drinks/week | 0.93 (0.42–2.09) | |
| | | | | | | | ≥3 drinks/week | 2.27 (1.28–4.03) | |
| Chew | Australia | Population- | Cross-sectional | IIEF-5 | ≥20 | 1,580 | None | 1 | Age, square of age, CVD, and cigarette smoking |
| et al. [20] | | Dased | | | | | Current drinkers | 0.57 (0.25–1.29) | |
| | | | | | | | <1 drink/week | 0.78 (0.31–2.00) | |
| | | | | | | | 120 drinks/week | 0.54 (0.24-1.24) | |
| | | | | | | | 2130 drinks/week | 0.56 (0.22-1.42) | |
| | | | | | | | >30 drinks/week | 0.59 (0.23-1.53) | |
| | | | | | | | | | |

Table 1 (continued)

| | (| | | | | | | | |
|-----------------------------|--------------------|-----------------------|---------------------------------|-------------------------|------------|----------------|------------------------|-------------------------|--|
| Author, reference | Country/ region | Population sources | Design type | Definition | Age, years | Sample size | Alcohol consumption | ORs (95% CI) | Adjustments |
| Malavige | Sri Lanka | Type 2 diabetes | Type 2 diabetes Cross-sectional | IIEF-5 | 55.6±10.4 | 253 | None | 1 | |
| et al. [34]** | | | | | | | 1–30 units/week | 0.195 (0.053–0.720) | |
| | | | | | | | 31-60 units/week | 0.293 (0.115–0.745) | |
| | | | | | | | >61 units/week | 0.512 (0.144–1.824) | |
| Rhoden | Brazil | Patients | Cross-sectional | IIEF-15 | 57.8±9.1 | 192 | None | 1 | |
| et al. [33] ² | | | | | | | Drinking | 1.561 (0.559-4.361) | |
| Kupelian | USA | Population- | Cross-sectional | IIEF-5 | 44.3±0.52 | 2,301 | None | 1 | Age |
| et al. [32] ² | | based | | | | | <1 drink/day | 0.54 ($0.37-0.80$) | |
| | | | | | | | 13 drinks/day | 0.50 (0.30–0.82) | |
| | | | | | | | 3+ drinks/day | 0.61 (0.35-1.05) | |
| He | China | Population- | Cross-sectional | Questionnaire 35-74 | 35-74 | 7,684 | None | 1 | Age, not high school graduate, cigarette smoking, |
| et al. [51] ² | | Dased | | | | | Drinking | 1.02 (0.81–1.29) | pnysical inactivity, diabetes, nypertension, overweight, and hypercholesterolemia |
| Asboe | European | HIV-positive | Cross-sectional | IIEF-15 | | 668 | None | 1 | |
| et al. [20] ⁻ | | | | | | | Drinking | 0.687 (0.486–0.972) | |
| Francis | USA | Population- | Cross-sectional | Questionnaire 54.4±0.32 | | 1,370 | Abstains | 1 | Age, race, obstructive symptoms, hypertensive, |
| et at. [29] ^{-, -} | | Dased | | | | | 1-7 drinks/week | 0.49 (0.3-0.95) | diagnosed diabetes, instory of CVD, user of ADEPmeds, and cigarette use |
| | | | | | | | 7+ drinks/week | 0.52 (0.3-1.1) | |
| | | | | | | | | | |

Table 1 (continued)

Erectile Dysfunction and Alcohol Consumption

| | manin | | | | | | | | |
|---------------------------------------|--------------------|-------------------------------|--------------------------|---------------------|------------|----------------|------------------------|------------------------|---|
| Author, reference | Country/ region | Population sources | Design type | Definition | Age, years | Sample size | Alcohol consumption | ORs (95% CI) | Adjustments |
| Bacon | USA | Population- | Prospective ³ | Questionnaire 40–75 | 40-75 | 22,086 | None | 1 | Age and marital status |
| et al. [8] ¹ | | based | | | | | 0.1–4.9 gm/day | 1.0 (0.9–1.1) | |
| | | | | | | | 5.0–14.9 gm/day | 1.0 (0.9–1.1) | |
| | | | | | | | 15-29.9 gm/day | 1.0 (0.9–1.1) | |
| | | | | | | | ≥30 gm/day | 1.1 (1.0-1.2) | |
| Hwang | Taiwan | Population- | Cross-sectional | IIEF-5 | ≥40 | 680 | None | 1 | |
| et al. [28] ¹ | | based | | | | | Drinking | 0.9 (0.6-1.4) | |
| Štulhofer | Croatia | Population- | Cross-sectional | Questionnaire 54±12 | 54±12 | 615 | ≤1 drink/month | 1 | Age, education, BMI, income, smoking, |
| et al. [27] ^{45 ±} | | based | | | | | ≤1 drink/week | 0.3 (0.1-1.0) | medication, talking about sex with a partner, traditional sex attitudes, physical activity, stress, and anxiety |
| | | | | | | | 26 drinks/week | 0.4 (0.2–1.0) | |
| | | | | | | | Daily | 0.6 (0.4–1.3) | |
| Millett | Australia | Population- | Cross-sectional | Self-reported | 16-59 | 8,367 | Nondrinker | 1 | Age, tobacco, employment, education, taking meds |
| et al. [26] ^{1, 2} | | based | | | | | 1–4 drinks/day | 0.36 (0.28–0.45) | for CVD, and diabetes |
| | | | | | | | 4+ drinks/day | 0.89 (0.81-1.34) | |
| Kalter- | Israel | Diabetes | Cross-sectional | IIEF-15 | >18 | 1,040 | None | 1 | Age, physical activity, diabetes duration, HAIC, |
| Leibovici et al. [13] ¹ | | | | | | | Drinking | 0.70 (0.51-0.97) | any microvascular complications, cardiovascular disease, and diuretics |
| Cho | Korea | Type 2 diabetes Cross-section | s Cross-sectional | Modified | 53.8±6.65 | 1,312 | None | 1 | Age, duration diabetes, neuropathy, use of insulin, |
| et al. [62] . | | mellitus | | C-1111 | | | Drinking | 0.602 (0.464–0.780) | macrovascular disease, HDA1C, exercise |
| Polsky | | | Case-control | Diagnosed | 50-80 | 335 | <1 drink/week | 1 | Age, education level, diabetes history, and pack- |
| et al. [oc] .te | Canada | | | | | | 17 drinks/week | 1.96 (1.01–3.80) | years |
| | | | | | | | ≥8 drinks/week | 2.09 (1.08–4.05) | |
| | | | | | | | | | |

 Table 1 (continued)

Urol Int 2021;105:969–985 DOI: 10.1159/000508171 Li/Song/Zhang/Zhang

| Table 1 (continued) | ntinued) | | | | | | | | |
|-----------------------------|------------------------|----------------------------|--------------------------|---------------------|-----------------|----------------|------------------------|-------------------------|---|
| Author, reference | Country/ region | Population sources | Design type | Definition | Age, years | Sample size | Alcohol consumption | ORs (95% CI) | Adjustments |
| Austoni | Italy | Population- | Cross-sectional | Diagnosed | | 16,724 | None | 1 | Age, marital status, education, BMI, physical |
| et al. [24] ^{1, 2} | | based | | | | | ≤3 drinks/day | 0.9 (0.8–1.0) | activity, diabetes, hypertension, CVD, and hypercholesterolemia |
| | | | | | | | >3 drinks/day | 1.0 (0.7–1.9) | |
| Shiri | Finland | Population- | Prospective ³ | National | ≥50 | 1,130 | None | 1 | Age, education, marital status, place of residence, |
| et al. [54] ** | | Dased | | conterence | | | 1-150 (g/week) | 1.0 (0.7-1.4) | BMLI, smoking, and corree consumption |
| | | | | | | | ≥151 (g/week) | 1.0 (0.7–1.6) | |
| Bai | China | Population- | Cross-sectional | IIEF-5 | 20–86 | 2,226 | None | 1 | Age |
| et al. [23]* | | Dased | | | | | Drinking | 0.69 (0.56–0.84) | |
| Nicolosi | Brazil, Italy, | Brazil, Italy, Population- | Cross-sectional | Questionnaire 40-70 | | 2,617 | None | 1 | Age, education, country, diabetes, heart disease, |
| et al. [22] ³² | Japan, and Malaysia | Dased | | | | | 1-7 drinks/week | 0.74 (0.53-1.02) | depression, lower urinary tract symptoms, tobacco, and physical activity |
| | | | | | | | ≥8 drinks/week | 0.73 (0.53–0.99) | |
| Akkus | Turkey | Population- | Cross-sectional | Questionnaire ≥40 | | 1,982 | None | 1 | Age, education, employment, income, region, |
| et al. [21] ¹ | | based | | | | | Drinking | 0.55 ($0.36-0.85$) | medical history, depression, international prostate screening score, and physical activity |
| Mak | Belgium | Population- | Cross-sectional | IIEF-15 | 40–69 years 799 | 799 | <2 drinks/day | 1 | Age |
| et al. [20] ² | | Dased | | | | | 24 drinks/day | 0.56 (0.37-0.84) | |
| | | | | | | | ≥4 drinks/day | 1.29 (0.88-1.88) | |
| Moreira | Brazil | Population- | Cross-sectional | National | 49.1 ± 8.4 | 337 | None | 1 | Age, smoking, and medical conditions |
| et al. [19] ⁻ | | Dased | | conterence | | | ≤3 drinks/day | 0.4 (0.2-1.0) | |
| | | | | | | | >3 drinks/day | 0.7 (0.2–2.4) | |
| | | | | | | | | | |

| Author, reference | Country/ region | Population sources | Design type | Definition | Age, years | size | Alconol consumption | ORs (95% CI) | Adjustments |
|-----------------------------|--------------------|-----------------------|-----------------|-------------------|------------|-------|-----------------------------|------------------|---|
| Fedele | Italy | Type 1 diabetic | Cross-sectional | Questionnaire | 20-69 | 1,383 | None | 1 | Age and duration of diabetes |
| et al. [18] ^{4, 2} | | patients | | | | | 17 glasses/week | 1.1 (0.8-1.5) | |
| | | | | | | | 814 glasses/week | 0.9 (0.6–1.3) | |
| | | | | | | | 1521 glasses/week | 1.1 (0.7-1.5) | |
| | | | | | | | ≥22 glasses/week | 1.3 (0.9–2.0) | |
| Fedele | Italy | iabetic | Cross-sectional | Questionnaire | 20-69 | 1,383 | None | 1 | Age and duration of diabetes |
| et al. [18] ^{1, 2} | | patients | | | | | 17 glasses/week | 0.9 (0.8–1.1) | |
| | | | | | | | 814 glasses/week | 0.9 (0.8-1.0) | |
| | | | | | | | 1,521 glasses/week 1.0 (0.7 | (0.7–1.2) | |
| | | | | | | | ≥22 glasses/week | 0.9 (0.8–1.0) | |
| Parazzini | Italy | Patients | Cross-sectional | Questionnaire ≥18 | ≥18 | 2,010 | None | 1 | Age, smoking, education, marital status, and age at |
| et al. [17]** | | | | | | | 17 glasses/week | 1.0 (0.6-1.5) | hist intercourse |
| | | | | | | | 814 glasses/week | 0.9 (0.6–1.3) | |
| | | | | | | | 1521 glasses/week | 0.8 (0.5-1.3) | |
| | | | | | | | ≥22 glasses/week | 0.7 (0.5-1.1) | |

978

Results

Search Results and Characteristics of Included Studies

A total of 46 studies including 216,461 participants were included (Table 1; Fig. 1, flowchart of study selection). 41 were cross-sectional studies [9–11, 13, 17–53], 3 were prospective studies [8, 54, 55], 1 was case-control study [56], and 1 was longitudinal study [57]. Thirty eight studies used "none"/"never"/"nondrinker"/"0 drinks/ week" as the control group, 8 studies used "noncurrent"/ "abstains"/"socially"/"monthly"/"≤1 drink/month"/"<1 drink/week"/"<1 drink/day"/"<2 drink/day" as the control group. Among the studies, 12 were conducted in Europe, 22 in Asia, 6 in South America, 5 in North America, and 1 was multinational. ED was assessed with the International Index of Erectile Function-5 (IIEF)-5 in 15 studies, with IIEF-15 in 8 studies, and through other methods in 23 studies. All of original studies included in this metaanalysis evaluating ED were blinded to consumption of alcohol.

Alcohol Consumption and Risk of ED

Based on the criteria of reference group, 44 studies about regular alcohol consumption versus reference group were included [8–11, 13, 17–19, 21–54, 56, 57]. Overall, there was significant association between regular alcohol consumption and ED (OR 0.89, 95% CI: 0.81– 0.97; $I^2 = 77.7\%$, Fig. 2a). There was no indication of publication bias (Egger's test, p = 0.37). In the stratified analysis, the pooled OR of ED for light to moderate and high alcohol consumption were 0.82 (95% CI: 0.72–0.94; $I^2 =$ 92.9%) and 0.82 (95% CI: 0.67–1.00; $I^2 = 93.5\%$), respectively (Fig. 2b, c).

In the subgroup analysis, the pooled OR of ED for regular alcohol consumption versus reference group was associated with a decreased risk of ED in population-based group (OR 0.87, 95% CI: 0.78–0.98), in definition of other methods about ED group (OR 0.86, 95% CI: 0.77–0.98), in the "yes" of adjusted group (OR 0.88, 95% CI: 0.81– 0.97), in moderate/complete ED group (OR 0.77, 95% CI: 0.63–0.95), and in complete ED group (OR 0.60, 95% CI: 0.43–0.84). However, the similar relation could not be found in other groups (Table 2).

The pooled OR of ED for light to moderate alcohol consumption versus reference group [8, 9, 17–19, 22, 24, 27, 29, 32, 35, 36, 38, 40, 54, 56] was associated with a decreased risk of ED in Europe group, in Asia group, in South America group, in population-based group, in definition of IIEF-5 and other methods about ED groups, in the "Yes" of adjusted and "no" of adjusted groups, in




Fig. 1. Flowchart of study selection. OR, odds ratio.

moderate/complete and complete ED groups. However, the similar relation could be found only in Asia group for high alcohol consumption versus reference group (Table 2) [8–11, 17–19, 24, 26, 32, 34, 35, 38, 40, 54]. No variable related to the source of heterogeneity was found in univariate and multivariate meta-regression analyses (data not shown).

Dose-Response Meta-Analysis

Overall, 17 studies were included in final dose-response meta-analysis [10, 11, 17, 18, 20, 22, 24, 26, 27, 29, 34–36, 40, 54–56]. The nonlinear relationship of alcohol consumption with ED was observed (p for nonlinearity <0.001; Fig. 3). Compared with never/lowest drinkers, the pooled ORs were 0.87 (95% CI: 0.83–0.91), 0.81 (95% CI: 0.76–0.86), 0.82 (95% CI: 0.78–0.87), 0.95 (95% CI: 0.90– 1.00), and 1.08 (95% CI: 1.01–1.16) for coffee consumptions of 4, 11, 14.5, 73, and 145.5 drinks/week, respectively.

Discussion

People may use alcohol and other substances to tackle sexual performance anxiety, enhance sexual performance, or overcome sexual dysfunction. A World Health Organization study for alcohol and high-risk sexual be-

| Study ID | OR (95% Cl) | % Weight |
|--|--|--------------|
| | | 2.67 |
| Fedele et al. 2000 | 1.09 (0.91, 1.31) | 3.67 |
| Fedele et al. 2000 | 0.91 (0.85, 0.97) | 4.28 |
| Parazzini et al. 2000 | 0.84(0.68, 1.03) | 3.47 |
| Akkus et al. 2002 | 0.55 (0.36, 0.85) | 2.10 |
| Moreira et al. 2002 | 0.47 (0.24, 0.93) | 1.19 |
| Nicolosi et al. 2003 | 0.73 (0.59, 0.92) | 3.38 |
| Shiri et al. 2004 | 1.00 (0.77, 1.30) | 3.10 |
| Bai et al. 2004 | 0.69 (0.56, 0.84) | 3.54 |
| Kalter-Leibovid et al. 2005 | 0.70 (0.51, 0.97) | 2.73 |
| Cho et al. 2005 | 0.60 (0.46, 0.78) | 3.14 |
| Polsky et al. 2005 | 2.02 (1.27, 3.23) | 1.92 |
| Austoni et al. 2005 | 0.91 (0.81, 1.01) | 4.11 |
| Bacon et al. 2006 Hwang et al. 2006 | 1.03 (0.98, 1.08) | 4.33 2.13 |
| Stulhofer et al. 2006 | 0.90 (0.60, 1.40) 0.48 (0.31, 0.75) | 2.13 |
| Millett et al. 2006 | 0.46 (0.31, 0.75) 0.56 (0.23, 1.37) | 2.06 |
| He et al. 2007 | 1.02 (0.81, 1.29) | 3.33 |
| Asboe et al. 2007 | 0.69 (0.49, 0.97) | 2.57 |
| Francis et al. 2007 | 0.50 (0.33, 0.77) | 2.10 |
| Malavige et al. 2008 | 0.31 (0.16, 0.59) | 1.26 |
| Rhoden et al. 2008 | 1.56 (0.56, 4.36) | 0.61 |
| Kupelian et al. 2008 | 0.54 (0.42, 0.71) | 3.09 |
| Chew et al. 2009 | 0.57 (0.25, 1.29) | 0.88 |
| Holden et al. 2010 | 0.86 (0.55, 1.33) | 2.05 |
| Stolic et al. 2010 | • 6.46 (0.79, 53.18) | 0.16 |
| Lee et al. 2010 | - 1.54 (0.94, 2.53) | 1.80 |
| Chao et al. 2011 | 4.67 (0.55, 39.32) | 0.16 |
| Christensen et al. 2011 | 1.23 (0.77, 1.95) | 1.95 |
| Jeong et al. 2011 | 0.88 (0.44, 1.73) | 1.18 |
| Wu et al. 2012 + | 0.96 (0.82, 1.13) | 3.82 |
| Olugbenga-Bello et al. 2013 | 0.92 (0.62, 1.30) | 2.45 |
| Stranne et al. 2013 | 1.16 (0.91, 1.47) | 3.27 |
| Weber et al. 2013 🔶 | 0.64 (0.56, 0.74) | 3.91 |
| Costa et al. 2014 — | ◆ 3.25 (1.41,7.51) | 0.86 |
| Benli et al. 2016 | | 0.86 |
| Furukawa et al. 2016 | 0.50 (0.29, 0.88) | 1.56 |
| Seid et al. 2017 | 1.02 (0.56, 1.85) | 1.42 |
| Clemente et al. 2017 | 1.19 (0.46, 3.09) | 0.69 |
| Van et al. 2017 🛛 🔜 🚽 | 1.82 (1.26, 2.64) | 2.43 |
| Costa et al. 2017 | 0.75 (0.35, 1.60) | 1.00 |
| Zhang et al. 2017 | 1.03 (0.83, 1.27) | 3.49 |
| Pozzi et al. 2018 | - 0.95 (0.43, 2.13) | 0.92 |
| Sanches et al. 2018 | 1.14 (0.80, 1.63) | 2.52 |
| Boeri et al. 2018 | 1.11 (0.58, 2.49) | 1.06 |
| Song et al. 2019 | - 1.64 (1.18, 2.27) | 2.70 |
| Overall ($l^2 = 77.7\%$, $p = 0.000$) | 0.89 (0.81, 0.97) | 100.00 |
| NOTE: Weights are from random effects analysis | 1 | |
| 0.0188 1 | 53.2 | |

Fig. 2. Forest plots of the association between ED and regular alcohol consumption (**a**) and light to moderate alcohol consumption (**b**) and high alcohol consumption (**c**). OR, odds ratio; CI, confidence interval; ED, erectile dysfunction. *(Figure continued on next page.)*

havior reported that 12% males in the general population consumed alcohol prior to first sexual intercourse due to perceived positive effect of alcohol to improve sexual pleasure. Furthermore, alcohol was commonly used prior to intercourse with commercial sex worker. However, in the long run, substance abuse could impact on sexual functioning negatively and may lead to the onset of sexual disorders [58].

The present meta-analysis, involving 216,461 participants from 46 studies, has evaluated the association be-

| Fedele et al. 2000 0.99 (0.82, 0.99) 8.68 Parazzini et al. 2001 0.49 (0.70, 1.22) 6.37 Moreira et al. 2002 0.49 (0.20, 1.00) 2.21 Nicciosi et al. 2003 0.73 (0.55) 0.73 (0.55) 7.25 Shiri et al. 2005 2.00 (1.27, 3.23) 4.41 Austoni et al. 2005 0.99 (0.80, 1.00) 8.22 Bacor et al. 2006 0.90 (0.81, 0.75) 4.70 Francis et al. 2007 0.59 (0.33, 0.77) 4.70 Francis et al. 2008 0.54 (0.37, 0.80) 5.28 Chew et al. 2010 0.63 (0.34, 1.17) 3.21 Holden et al. 2010 0.74 (0.34, 1.64) 2.25 Weber et al. 2010 0.74 (0.34, 1.64) 2.25 Verail (ℓ^{-} 9.29%, ρ = 0.000) 0.82 (0.72, 0.94) 1000 NOTE: Weights are from random effects analysis 0.66 (0.67, 0.70) 9.00 Operazini et al. 2002 0.73 (0.55, 1.00) 7.36 Study 0.82 (0.72, 0.94) 1000 (0.70, 1.60) 6.83 Study 0.79 (0.02, 2.04) 1000 (0.70, 1.60) 6.83 Study 0.79 (0.20, 2.04) 1000 (0.70, 1.60) 6.83 | Study ID | OR (95% Cl) | % Weight |
|---|---|---|--|
| Parazzini et al. 2000 Parazzini et al. 2002 Moreira et al. 2003 Nicolosi et al. 2004 Polsky et al. 2005 Sulhofer et al. 2005 Chew et al. 2006 Christensen et al. 2010 Difference analysis Difference analysis Differen | Fedele et al. 2000 | 1.02 (0.80, 1.30) | 7.03 |
| Moreira et al. 2002 0.40 (0.20, 1.00) 2.21 Nicolosi et al. 2003 0.73 (0.59, 0.22) 7.25 Shiri et al. 2004 0.00 (0.70, 1.40) 5.74 Polsky et al. 2005 2.20 (127, 3.23) 4.41 Austoni et al. 2006 0.90 (0.80, 1.00) 8.52 Bacon et al. 2006 0.00 (0.94, 1.06) 8.88 Stuhofer et al. 2006 0.54 (0.37, 0.80) 5.28 Chew et al. 2007 0.50 (0.33, 0.77) 4.79 Kupelian et al. 2008 0.54 (0.37, 0.80) 5.28 Chew et al. 2010 0.70 (0.60, 0.90) 7.54 Holden et al. 2010 0.74 (0.34, 1.64) 2.25 Veezer et al. 2011 0.74 (0.34, 1.64) 2.25 Veezer et al. 2013 0.68 (0.67, 0.70) 9.00 NOTE: Weights are from random effects analysis 0.74 (0.55, 1.00) 7.36 Parazzini et al. 2000 0.74 (0.55, 1.00) 7.36 Fedele et al. 2000 0.70 (0.20, 2.40) 1.93 Moreira et al. 2002 0.70 (0.20, 2.40) 1.93 Moreira et al. 2004 0.70 (0.20, 2.40) 1.93 Austoni et al. 2000 0.70 (0.20, 2.40) 1.93 | Fedele et al. 2000 | 0.90 (0.82, 0.99) | 8.68 |
| Nicolosi et al. 2003 Shiri et al. 2004 Polsky et al. 2005 Auxtoni et al. 2005 Bacon et al. 2006 Chew et al. 2007 Chistensen et al. 2010 Chistensen et al. 2000 Parazzini et al. 2000 Parazzini et al. 2000 Chi (Da. 2, 10.1) Bacon et al. 2000 Chi (Da. 2, 10.1) Chi (Da. 1, 10, 10.2) Chi (Da. 2, 10.1) Chi (Da. 1, 10, 10.2) Chi (Da. 2, 10.2) Chi (Da. 1, 10, 10.2) Chi (Da. 2, 10.2) Chi (Da. 1, 10, | Parazzini et al. 2000 | 0.94 (0.70, 1.26) | 6.37 |
| Shiri et al. 2004 Polsky et al. 2005 Bacon et al. 2005 Bacon et al. 2006 Sulpder et al. 2007 Chew et al. 2009 0.63 (0.34, 1.17) 0.57 (0.40, 0.90, 0.80, 0.00) Chew et al. 2010 Chew et al. 2010 Chew et al. 2010 0.63 (0.34, 1.17) 0.57 (0.34, 1.64) 0.2 1 5 Sulpder 0.2 0.2 1 5 Sulpder 0.2 1 5 Sulpder 0.2 1 5 Sulpder 0.2 1 5 Sulpder 0.2 1 5 Sulpder 0.2 1 5 Sulpder 0.2 0 5 Sulpder 0.2 0 Sulpder 0.2 0 5 Sulpder 0 | Moreira et al. 2002 🖌 🖌 | 0.40 (0.20, 1.00) | 2.21 |
| Polsky et al. 2005 Austoni et al. 2006 Stulhofer et al. 2006 Stulhofer et al. 2006 Chew et al. 2007 Kupelian et al. 2007 Kupelian et al. 2008 Chew et al. 2009 Octa (0.34, 0.17) Christensen et al. 2011 OC Christensen et al. 2010 Christensen et al. 2000 Shiri et al. 2000 Christensen et al. 2010 Christensen et al. 2000 Christensen et al. 2010 Christensen et al. 2017 Christensen | Nicolosi et al. 2003 - • | 0.73 (0.59, 0.92) | 7.25 |
| Austoni et al. 2005 Bacon et al. 2006 Studhofer et al. 2007 Kupelian et al. 2008 Chew et al. 2010 0.2 Study D Study Study D Study Study Study D Study | Shiri et al. 2004 | - 1.00 (0.70, 1.40) | 5.74 |
| Bacon et al. 2006 Stulhofer et al. 2006 Stulhofer et al. 2007 Kupelian et al. 2008 Chew et al. 2010 Christensen et al. 2010 0.2 1 Study DC Fedele et al. 2000 Christensen et al. 2000 Christensen et al. 2000 Parazzini et al. 2000 Christensen et al. 2000 Parazzini et al. 2000 Christensen et al. 2010 Christensen et al. 2011 Christensen et al. 2011 Christensen et al. 2010 Christensen et al. 2011 Christensen et al. 2010 Christensen et al. 2011 Christensen et al. 2010 Christensen et al. 2011 Christensen et al. 2017 Christensen et al. 2017 Chris | Polsky et al. 2005 - | • 2.02 (1.27, 3.23) | 4.41 |
| Stulhofer et al. 2006 Francis et al. 2007 Kupelian et al. 2008 Chew et al. 2009 Holden et al. 2010 Christensen et al. 2011 0.2 1.54 (0.37, 0.80) 0.63 (0.34, 1.17) 1.54 (0.37, 0.80) 0.63 (0.34, 1.17) 1.54 (0.37, 0.80) 7.54 0.37 (0.60, 0.90) 0.68 (0.67, 0.70) 0.00 NOTE: Weights are from random effects analysis 0.2 1 5 Study D 0.2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 | Austoni et al. 2005 | 0.90 (0.80, 1.00) | 8.52 |
| Francis et al. 2007 Kupelian et al. 2008 Chew et al. 2010 Christensen et al. 2010 0.2 1 5 Study D CR (95% CI) 0.2 1 0.2 1 0.2 1 0.2 1 0 0.2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 | Bacon et al. 2006 🔶 | 1.00 (0.94, 1.06) | 8.88 |
| Kupelian et al. 2008 0.54 (0.37, 0.80) 5.28 Chew et al. 2010 0.63 (0.34, 1.17) 3.21 Holden et al. 2010 0.70 (0.60, 0.90) 7.54 Lee et al. 2010 0.74 (0.34, 1.64) 2.25 Weber et al. 2013 0.68 (0.67, 0.70) 9.00 NOTE: Weights are from random effects analysis 0.2 1 5 Study 0.2 1 5 5 Study 0.2 1 5 5 Peckle et al. 2000 0.91 (0.82, 1.01) 8.75 Fedele et al. 2000 0.74 (0.55, 1.00) 7.36 Parazzini et al. 2002 0.70 (0.20, 2.40) 1.93 Moreira et al. 2005 1.10 (1.00, 1.20) 8.79 Bacon et al. 2005 1.10 (1.00, 1.20) 8.79 Bacon et al. 2006 0.57 (0.30, 1.12) 4.40 Millett et al. 2006 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Millett et al. 2006 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6. | Stulhofer et al. 2006 | 0.48 (0.31, 0.75) | 4.70 |
| Chew et al. 2009 Holden et al. 2010 Christensen et al. 2011 Weber et al. 2013 Overall (ℓ^2 = 93,5%, p = 0.000) NOTE: Weights are from random effects analysis O2 1 5 Study D02 0 Study D02 0 D02 0 D0 | Francis et al. 2007 | 0.50 (0.33, 0.77) | 4.79 |
| Holden et al. 2010 Lee et al. 2010 Christensen et al. 2011 0.2 5 5 5 5 5 5 5 5 5 5 5 5 5 | Kupelian et al. 2008 🛛 🔶 | 0.54 (0.37, 0.80) | 5.28 |
| Lee et al. 2010 1.54 (0.94, 2.53) 4.16 Christensen et al. 2011 0.74 (0.34, 1.64) 2.25 Weber et al. 2013 0.68 (0.67, 0.70) 9.00 Overall (l ² = 92.9%, p = 0.000) 0.82 (0.72, 0.94) 100.00 NOTE: Weights are from random effects analysis 0.2 1 5 Study 0.2 1 5 5 Study 0.2 1 5 5 Fedele et al. 2000 0.71 (0.55, 1.00) 7.36 Parazzini et al. 2000 0.70 (0.20, 2.40) 1.93 Moreira et al. 2002 1.00 (0.70, 1.60) 6.39 Shiri et al. 2004 1.00 (0.70, 1.60) 6.39 Austoni et al. 2005 1.00 (0.70, 1.60) 6.39 Bacon et al. 2006 0.55 (0.38, 0.79) 6.78 Millett et al. 2006 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.00 (0.80, 1.60) 6.99 Christensen et al. 2016 1.00 (0.80, 1.60) 6.99 Christensen et al. 2016 1.00 (0.29, 0.88) 5.19 Zhang et al. 2017 0.32 | Chew et al. 2009 | 0.63 (0.34, 1.17) | 3.21 |
| Christensen et al. 2011 Weber et al. 2013 Overall (l ² = 92.9%, p = 0.000) NOTE: Weights are from random effects analysis 0.2 1 5 Study D D CR (95% CI) Weight Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Millett et al. 2008 Christensen et al. 2010 Christensen et al. 2011 Weber et al. 2010 Christensen et al. 2011 Weber et al. 2010 Christensen et al. 2011 Christensen et al. 2011 Christensen et al. 2011 Christensen et al. 2010 Christensen et al. 2017 Christensen et al. 2017 Christen | Holden et al. 2010 | | 7.54 |
| Weber et al. 2013 0.68 (0.67, 0.70) 9.00 Overall (l ² = 92.9%, p = 0.000) 0.82 (0.72, 0.94) 100.00 NOTE: Weights are from random effects analysis 0.2 1 5 Study 0.2 1 5 Study 0.2 0.91 (0.82, 1.01) 8.75 Fedele et al. 2000 0.74 (0.55, 1.00) 7.36 Parazzini et al. 2000 0.70 (0.20, 2.40) 1.93 Moreira et al. 2002 1.00 (0.70, 1.60) 6.39 Shiri et al. 2004 1.00 (0.70, 1.60) 6.39 Austoni et al. 2005 1.10 (1.00, 1.20) 8.79 Bacon et al. 2006 0.56 (0.23, 1.37) 3.14 Malavige et al. 2008 0.57 (0.30, 1.12) 4.40 Malavige et al. 2008 0.57 (0.30, 1.12) 4.40 Chew et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.50 (0.29, 0.88) 5.19 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.33 (0.81, 2.7) 0.13 Overall (l ² = 9.5%, p = 0.000) 0.82 (0.67, 1 | | , | |
| Overall (l ² = 92.9%, p = 0.000) 0.82 (0.72, 0.94) 100.00 NOTE: Weights are from random effects analysis 0.2 1 5 Study ID 0.2 1 5 Study ID 0.2 1 5 Study ID 0.2 1 8.75 Fedele et al. 2000 0.74 (0.55, 1.00) 7.36 Parazzini et al. 2000 0.70 (0.20, 2.40) 1.93 Moreira et al. 2002 1.00 (0.70, 1.60) 6.39 Shiri et al. 2004 1.00 (0.70, 1.60) 6.39 Austoni et al. 2005 1.10 (1.00, 1.20) 8.79 Bacon et al. 2006 0.56 (0.23, 1.37) 3.14 Millett et al. 2006 0.51 (0.16, 0.59) 4.49 Malavige et al. 2008 0.55 (0.38, 0.79) 6.78 Chew et al. 2009 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 0.62 (0.60, 0.64) 8.94 Weber et al. 2013 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.30 (0.83, 1.27) 0.13 Oxerall (l ² = 93,5%, p = 0.000) 0.82 (0.67, 1.00) | | | |
| NOTE: Weights are from random effects analysis 0.2 1 5 Study ID 0.2 1 5 Fedele et al. 2000 0.74 (0.55, 1.00) 7.36 Parazzini et al. 2000 0.74 (0.55, 1.00) 7.36 Parazzini et al. 2000 0.70 (0.20, 2.40) 1.93 Moreira et al. 2002 1.00 (0.70, 1.60) 6.39 Shiri et al. 2004 1.00 (0.70, 1.90) 5.65 Austoni et al. 2005 1.10 (1.00, 1.20) 8.79 Bacon et al. 2006 0.55 (0.38, 0.79) 6.78 Millett et al. 2008 0.57 (0.30, 1.12) 4.40 Molaging et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.52 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.30 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | | | |
| Study ID OR (95% Cl) % Weight Fedele et al. 2000 0.91 (0.82, 1.01) 8.75 Fedele et al. 2000 0.74 (0.55, 1.00) 7.36 Parazzini et al. 2000 0.70 (0.20, 2.40) 1.93 Moreira et al. 2002 1.00 (0.70, 1.60) 6.39 Shiri et al. 2004 1.00 (0.70, 1.90) 5.65 Austoni et al. 2005 1.10 (1.00, 1.20) 8.79 Bacon et al. 2006 0.56 (0.23, 1.37) 3.14 Millett et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2009 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 0.52 (0.29, 0.88) 5.19 Weber et al. 2013 0.50 (0.29, 0.88) 5.19 Furukawa et al. 2016 1.03 (0.83, 1.27) 0.13 Oxerall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | | 0.82 (0.72, 0.94) | 100.00 |
| Fedele et al. 2000 0.74 (0.55, 1.00) 7.36 Parazzini et al. 2000 0.70 (0.20, 2.40) 1.93 Moreira et al. 2002 1.00 (0.70, 1.60) 6.39 Shiri et al. 2004 1.00 (0.70, 1.90) 5.65 Austoni et al. 2005 1.10 (1.00, 1.20) 8.79 Bacon et al. 2006 0.56 (0.23, 1.37) 3.14 Millett et al. 2008 0.51 (0.16, 0.59) 4.49 Malavige et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 0.52 (0.29, 0.88) 5.19 Weber et al. 2013 0.50 (0.29, 0.88) 5.19 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.33 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | 0.2 1 | 5 | |
| Parazzini et al. 2000 0.70 (0.20, 2.40) 1.93 Moreira et al. 2002 1.00 (0.70, 1.60) 6.39 Shiri et al. 2004 1.00 (0.70, 1.60) 6.39 Austoni et al. 2005 1.10 (1.00, 1.20) 8.79 Bacon et al. 2006 0.56 (0.23, 1.37) 3.14 Millett et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.50 (0.29, 0.88) 5.19 Furukawa et al. 2016 1.03 (0.83, 1.27) 0.13 Zhang et al. 2017 0.82 (0.67, 1.00) 100.00 | | | |
| Moreira et al. 2002 1.00 (0.70, 1.60) 6.39 Shiri et al. 2004 1.00 (0.70, 1.60) 6.39 Austoni et al. 2005 1.00 (0.70, 1.90) 5.65 Bacon et al. 2006 1.10 (1.00, 1.20) 8.79 Millett et al. 2006 0.56 (0.23, 1.37) 3.14 Millett et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.382 (0.67, 1.00) 100.00 | | OR (95% CI) | Weight |
| Shiri et al. 2004 1.00 (0.70, 1.80) 5.35 Austoni et al. 2005 1.00 (0.70, 1.90) 5.65 Bacon et al. 2006 0.56 (0.23, 1.37) 3.14 Millett et al. 2006 0.56 (0.23, 1.37) 3.14 Millett et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 1.03 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 | OR (95% Cl) | Weight 8.75 |
| Austoni et al. 2005 1.00 (0.70, 1.90) 5.65 Bacon et al. 2006 1.10 (1.00, 1.20) 8.79 Millett et al. 2006 0.56 (0.23, 1.37) 3.14 Malavige et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Chew et al. 2009 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.33 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 | OR (95% Cl) | Weight 8.75 7.36 |
| Bacon et al. 2006 1.10 (1.00, 1.20) 8.79 Millett et al. 2006 0.56 (0.23, 1.37) 3.14 Malavige et al. 2008 0.31 (0.16, 0.59) 4.49 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Holden et al. 2009 1.10 (0.80, 1.60) 6.99 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.32 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 | OR (95% Cl) | Weight 8.75 7.36 1.93 |
| Bacon et al. 2006 0.56 (0.23, 1.37) 3.14 Millett et al. 2006 0.31 (0.16, 0.59) 4.49 Malavige et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2009 0.57 (0.30, 1.12) 4.40 Holden et al. 2010 1.10 (0.80, 1.60) 6.99 Christensen et al. 2011 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.38 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 | OR (95% Cl) | Weight 8.75 7.36 1.93 6.39 |
| Millett et al. 2006 0.31 (0.16, 0.59) 4.49 Malavige et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Chew et al. 2009 1.10 (0.80, 1.60) 6.99 Holden et al. 2010 1.53 (0.91, 2.59) 5.45 Christensen et al. 2011 0.62 (0.60, 0.64) 8.94 Weber et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 0.31 (0.16, 0.59) 0.43 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 | OR (95% Cl) 0.91 (0.82, 1.01) 0.74 (0.55, 1.00) 0.70 (0.20, 2.40) 1.00 (0.70, 1.60) 1.00 (0.70, 1.90) | Weight 8.75 7.36 1.93 6.39 5.65 |
| Malavige et al. 2008 0.55 (0.38, 0.79) 6.78 Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Chew et al. 2009 1.10 (0.80, 1.60) 6.99 Holden et al. 2010 1.53 (0.91, 2.59) 5.45 Christensen et al. 2011 0.62 (0.60, 0.64) 8.94 Weber et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 1.03 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 | OR (95% Cl) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 |
| Kupelian et al. 2008 0.57 (0.30, 1.12) 4.40 Chew et al. 2009 1.10 (0.80, 1.60) 6.99 Holden et al. 2010 1.53 (0.91, 2.59) 5.45 Christensen et al. 2011 0.62 (0.60, 0.64) 8.94 Weber et al. 2013 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 1.03 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 | OR (95% Cl) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 |
| Chew et al. 2009 1.10 (0.80, 1.60) 6.99 Holden et al. 2010 1.53 (0.91, 2.59) 5.45 Christensen et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 1.03 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Malavige et al. 2008 | OR (95% Cl) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 4.49 |
| Christensen et al. 2010 1.53 (0.91, 2.59) 5.45 Weber et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 1.03 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Malavige et al. 2008 | OR (95% Cl) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 4.49 6.78 |
| Weber et al. 2013 0.62 (0.60, 0.64) 8.94 Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 1.03 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Millett et al. 2008 Chew et al. 2009 | OR (95% Cl) 0.91 (0.82, 1.01) 0.74 (0.55, 1.00) 0.70 (0.20, 2.40) 1.00 (0.70, 1.60) 1.00 (0.70, 1.60) 1.00 (0.70, 1.90) 1.10 (1.00, 1.20) 0.56 (0.23, 1.37) 0.31 (0.16, 0.59) 0.55 (0.38, 0.79) 0.57 (0.30, 1.12) 0.57 (0.30, 1.12) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 4.49 6.78 4.40 |
| Furukawa et al. 2016 0.50 (0.29, 0.88) 5.19 Zhang et al. 2017 1.03 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Malavige et al. 2008 Chew et al. 2009 Holden et al. 2010 | OR (95% Cl) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 4.49 6.78 4.40 6.99 |
| Zhang et al. 2017 1.03 (0.83, 1.27) 0.13 Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Malavige et al. 2008 Chew et al. 2009 Holden et al. 2010 Christensen et al. 2011 | OR (95% Cl) 0.91 (0.82, 1.01) 0.74 (0.55, 1.00) 0.70 (0.20, 2.40) 1.00 (0.70, 1.60) 1.00 (0.70, 1.90) 1.10 (1.00, 1.20) 0.56 (0.23, 1.37) 0.31 (0.16, 0.59) 0.55 (0.38, 0.79) 0.57 (0.30, 1.12) 1.10 (0.80, 1.60) 1.53 (0.91, 2.59) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 4.49 6.78 4.40 6.99 5.45 |
| Overall (l ² = 93.5%, p = 0.000) 0.82 (0.67, 1.00) 100.00 | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Millett et al. 2008 Kupelian et al. 2008 Chew et al. 2009 Holden et al. 2010 Christensen et al. 2011 Weber et al. 2013 | OR (95% Cl) 0.91 (0.82, 1.01) 0.74 (0.55, 1.00) 0.70 (0.20, 2.40) 1.00 (0.70, 1.60) 1.00 (0.70, 1.60) 1.00 (0.70, 1.90) 1.10 (1.00, 1.20) 0.56 (0.23, 1.37) 0.31 (0.16, 0.59) 0.55 (0.38, 0.79) 0.57 (0.30, 1.12) 1.10 (0.80, 1.60) 1.53 (0.91, 2.59) 0.62 (0.60, 0.64) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 4.49 6.78 4.40 6.99 5.45 8.94 |
| | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Millett et al. 2008 Kupelian et al. 2008 Chew et al. 2009 Holden et al. 2010 Christensen et al. 2011 Weber et al. 2013 Furukawa et al. 2016 | OR (95% Cl) 0.91 (0.82, 1.01) 0.74 (0.55, 1.00) 0.70 (0.20, 2.40) 1.00 (0.70, 1.60) 1.00 (0.70, 1.60) 1.00 (0.70, 1.90) 1.10 (1.00, 1.20) 0.56 (0.23, 1.37) 0.31 (0.16, 0.59) 0.55 (0.38, 0.79) 0.57 (0.30, 1.12) 1.10 (0.80, 1.60) 1.53 (0.91, 2.59) 0.62 (0.60, 0.64) 0.50 (0.29, 0.88) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 4.49 6.78 4.40 6.99 5.45 8.94 5.19 |
| | ID Fedele et al. 2000 Fedele et al. 2000 Parazzini et al. 2000 Moreira et al. 2002 Shiri et al. 2004 Austoni et al. 2005 Bacon et al. 2006 Millett et al. 2006 Malavige et al. 2008 Chew et al. 2008 Chew et al. 2010 Christensen et al. 2011 Weber et al. 2013 Furukawa et al. 2016 Zhang et al. 2017 | OR (95% Cl) 0.91 (0.82, 1.01) 0.74 (0.55, 1.00) 0.70 (0.20, 2.40) 1.00 (0.70, 1.60) 1.00 (0.70, 1.90) 1.10 (1.00, 1.20) 0.56 (0.23, 1.37) 0.31 (0.16, 0.59) 0.55 (0.38, 0.79) 0.57 (0.30, 1.12) 1.10 (0.80, 1.60) 1.53 (0.91, 2.59) 0.62 (0.60, 0.64) 0.50 (0.29, 0.88) 1.03 (0.83, 1.27) | Weight 8.75 7.36 1.93 6.39 5.65 8.79 3.14 4.49 6.78 4.40 6.99 5.45 8.94 5.19 0.13 |

981

| 1 | reference | kegular alconol consumpuon versus reference | versus | TIBUL 10 II | Light to moretate versus reference | nce | mgn ver | high versus reference | |
|-------------------------|---------------|--|-------------|---------------|------------------------------------|-------------|---------------|-----------------------|--------------------|
| | studies, n | OR (95% CI) | $I^{2}, \%$ | studies, n | OR (95% CI) | $I^{2}, \%$ | studies, n | OR (95% CI) | I ² , % |
| Overall | 44 | 0.89 (0.81-0.97) | 77.70 | 16 | 0.82 (0.72-0.94) | 92.90 | 15 | 0.82 (0.67–1.00) | 93.50 |
| Region | | | | | | | | | |
| Europe | 11 | 0.93(0.84 - 1.03) | 54.80 | 9 | 0.89(0.81 - 0.99) | 36.40 | 5 | 0.98(0.83 - 1.16) | 44.40 |
| Asia | 22 | 0.85(0.73 - 1.00) | 77.50 | 4 | 0.77 ($0.61 - 0.97$) | 71.50 | 7 | 0.67 (0.50 - 0.91) | 84.00 |
| South America | 6 | 1.11(0.68 - 1.81) | 64.10 | 1 | 0.40(0.18 - 0.89) | I | 1 | 0.70 (0.20-2.42) | I |
| North America | 4 | 0.86(0.53 - 1.38) | 92.40 | 4 | 0.86(0.53 - 1.38) | 89.30 | 2 | 0.79(0.40-1.57) | 92.20 |
| Multinational | 1 | 0.73 (0.59-0.92) | | 1 | 0.73 (0.59–0.92) | | | | |
| Population sources | | | | | | | | | |
| Population-based | 25 | 0.87(0.78 - 0.98) | 81.80 | 13 | 0.74(0.63 - 0.88) | 93.30 | 11 | 0.87(0.67 - 1.13) | 94.30 |
| Others | 19 | $0.92\ (0.78 - 1.08)$ | 70.10 | 3 | 1.06(0.84 - 1.35) | 74.10 | 4 | 0.74(0.55 - 1.01) | 80.30 |
| Definition about ED | | | | | | | | | |
| IIÉF-5 | 15 | 0.94(0.76 - 1.17) | 79.50 | 2 | 0.56(0.41 - 0.78) | 0.00 | 4 | $0.59\ (0.35{-}1.00)$ | 84.10 |
| IIEF-15 | 8 | 0.99(0.71 - 1.37) | 54.00 | | | | | | |
| Others | 21 | 0.86(0.77 - 0.95) | 81.40 | 14 | 0.85(0.73 - 0.98) | 93.70 | 11 | 0.90(0.72 - 1.13) | 94.70 |
| Adjusted | | | | | | | | | |
| Yes | 30 | 0.88(0.81 - 0.97) | 78.50 | 14 | 0.85(0.75 - 0.95) | 78.00 | 12 | 0.90(0.79 - 1.03) | 63.80 |
| No | 14 | 0.92 (0.71–1.17) | 72.70 | 2 | 0.68(0.66-0.70) | 0.00 | 3 | 0.67(0.34 - 1.33) | 87.40 |
| Grade of ED | | | | | | | | | |
| Light/moderate/complete | 31 | 0.97 (0.87 - 1.07) | 69.90 | 7 | 0.96(0.85 - 1.08) | 49.40 | 10 | 0.86(0.72 - 1.03) | 65.40 |
| Moderate/complete | 10 | 0.77 (0.63–0.95) | 87.10 | 7 | 0.76(0.61 - 0.95) | 96.20 | 4 | 0.88 (0.56–1.37) | 97.90 |
| Complete | 3 | 0.60(0.43 - 0.84) | 45.30 | 2 | 0.52(0.39 - 0.70) | 0.00 | 1 | 0.55(0.38-0.79) | |

982

Table 2. Subgroup analysis

Urol Int 2021;105:969–985 DOI: 10.1159/000508171

Li/Song/Zhang/Zhang

tween ED and alcohol consumption. Overall, it has shown that regular alcohol consumption was significantly associated with a reduced risk of ED. The results of this study are also consistent with a previous metaanalysis [59]. However, it was different from the other one [60]. In the stratified analysis, the present metaanalysis showed that light to moderate alcohol consumption was correlated with a decreased risk of ED, instead of high alcohol consumption. Furthermore, a nonlinear association of dose-response analysis was further found between alcohol consumption and ED risk, and the risk increased quickly in very heavy alcohol consumption level. A J-shaped relationship between alcohol consumption and risk of ED was observed. Based on the previous studies, we inferred that alcohol may be a 2-side sword. On the one hand, alcohol should be taken in moderate quantities in order to obtain the dual effect of disinhibition and relaxation. On the other hand, alcohol abuse can have lasting effects on the liver, leading to increased levels of estrogen and low levels of testosterone, both of which can contribute to ED [35, 61, 62]. It should be noted that nondrinkers were not the group with the lowest risk of ED, which might contribute to that nondrinkers might be formerly heavy drinkers and had quit due to some disease [63].

Significant heterogeneity was observed in this study, to explore the source of heterogeneity, meta-regression analysis and subgroup analysis were performed. However, the heterogeneity in results of subgroup analysis was still high, and no variable related to the source of heterogeneity was found in univariate and multivariate meta-regression analyses. One possible explanation may be the fact that as the residual confounders for metaanalysis of epidemiological studies are inevitable, although the adjusted measurement whenever available was applied, the effects of confounding could not be excluded completely. For example, the majority of crosssection studies might induce more recall and selection biases. Besides, wide range of age in included studies could also impact the heterogeneity. It is noted that the complete ED groups were significant in all of comparative groups, the studies included in the analysis were adjusted by confounding, on some level, the protective association between alcohol consumption and ED might be possible.

Several strengths could be highlighted in this study. First, the present meta-analysis provides the recent and most complete evidences on the association between ED risk and alcohol consumption. Second, the combined use




Fig. 3. Dose-response analysis between risk of ED and alcohol consumption with restricted cubic splines in a random-effects dose-response model. The solid line and the dashed long line represent the estimated relative risk and its 95% CI. The dashed short line represents the linear relationship. ED, erectile dysfunction; CI, confidence interval.

of categorical meta-analysis and dose-response analysis can provide more information [64]. Moreover, the result of Egger's test did not support the presence of major publication bias.

Except the high heterogeneity, several potential limitations should also be considered. First, confounding was inherent in all observational studies, and some bias in included studies could not be avoided, such as recall and selection biases, which cannot be solved at a meta-analysis level. Because of adjusting for different number of factors from different studies, each study had a different level of confounding. In addition, different categories of alcohol drinking, such as beer, wine, and liquor, had different affections [63]. The uniform measurement of alcohol drinking might cause measurement errors to some extent. Moreover, definitions of ED were skimblescamble, which load to the different summary estimate for each definition.

Conclusions

The present meta-analysis has indicated that regular alcohol consumption was significantly associated with a reduced risk of ED. Heavy alcohol consumers were not associated with ED risk. A J-shaped relationship between alcohol consumption and risk of ED was observed. But for all those, alcohol should be taken in moderate quantities in order to obtain the dual effect of disinhibition and relaxation. If taken chronically, it could provoke vascular damages. We should explain the results with cautions for all the limitations and further studies with larger sample sizes, as well as greater statistical power would be needed to confirm the conclusions.

Statement of Ethics

As our research focused on summarizing relationships and did not include animal experimental research or human body research, we considered that ethical approval was not required.

References

- Ahn TY, Park JK, Lee SW, Hong JH, Park NC, Kim JJ, et al. Prevalence and risk factors for erectile dysfunction in Korean men: results of an epidemiological study. J Sex Med. 2007; 4(5):1269–76.
- 2 Patel DV, Halls J, Patel U. Investigation of erectile dysfunction. Br J Radiol. 2012;85(Spec No 1):S69–78.
- 3 Maiorino MI, Bellastella G, Esposito K. Lifestyle modifications and erectile dysfunction: what can be expected? Asian J Androl. 2015 JanFeb;17(1):5–10.
- 4 Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7(4 Pt 2):1598– 607.
- 5 Simplicio JA, do Vale GT, Gonzaga NA, Leite LN, Hipólito UV, Pereira CA, et al. Reactive oxygen species derived from NAD(P)H oxidase play a role on ethanol-induced hypertension and endothelial dysfunction in rat resistance arteries. J Physiol Biochem. 2017;73(1): 5–16.
- 6 Montezano AC, Touyz RM. Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research. Antioxid Redox Signal. 2014;20(1): 164–82.
- 7 Leite LN, do Vale GT, Simplicio JA, De Martinis BS, Carneiro FS, Tirapelli CR. Ethanolinduced erectile dysfunction and increased expression of pro-inflammatory proteins in the rat cavernosal smooth muscle are mediated by NADPH oxidase-derived reactive oxygen species. Eur J Pharmacol. 2017;804:82– 93.
- 8 Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. A prospective study of risk factors for erectile dysfunction. J Urol. 2006;176(1):217–21.
- 9 Weber MF, Smith DP, O'Connell DL, Patel MI, de Souza PL, Sitas F, et al. Risk factors for erectile dysfunction in a cohort of 108 477

Conflict of Interest Statement

All authors declare no competing interests.

Funding Sources

The authors declare they did not receive any funding.

Author Contributions

S.L. drafted the manuscript. J.M.S. and C.L.Z. revised the manuscript. S.L. and J.M.S. searched and selected relevant studies. S.L. and K.Z. extracted the data. K.Z. contributed to the data analysis. All authors read and approved the final manuscript.

Australian men. Med J Aust. 2013;199(2): 107–11.

- 10 Zhang X, Yang B, Li N, Li H. Prevalence and risk factors for erectile dysfunction in Chinese adult males. J Sex Med. 2017;14(10):1201–8.
- 11 Furukawa S, Sakai T, Niiya T, Miyaoka H, Miyake T, Yamamoto S, et al. Alcohol consumption and prevalence of erectile dysfunction in Japanese patients with type 2 diabetes mellitus: baseline data from the Dogo study. Alcohol. 2016;55:17–22.
- 12 Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139(3):161–8.
- 13 Kalter-Leibovici O, Wainstein J, Ziv A, Harman-Bohem I, Murad H, Raz I. Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care. 2005;28(7):1739–44.
- 14 Lakshman R, Garige M, Gong M, Leckey L, Varatharajalu R, Zakhari S. Is alcohol beneficial or harmful for cardioprotection? Genes Nutr. 2009;5(2):111–20.
- 15 Li J, Zhao H, Song JM, Zhang J, Tang YL, Xin CM. A meta-analysis of risk of pregnancy loss and caffeine and coffee consumption during pregnancy. Int J Gynaecol Obstet. 2015; 130(2):116–22.
- 16 Larsson SC, Orsini N, Wolk A. Alcohol consumption and risk of heart failure: a dose-response meta-analysis of prospective studies. Eur J Heart Fail. 2015;17(4):367–73.
- 17 Parazzini F, Menchini Fabris F, Bortolotti A, Calabrò A, Chatenoud L, Colli E, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol. 2000;37(1):43–9.
- Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, et al. Erectile dysfunction in type 1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol. 2000; 29(3):524–31.

- 19 Moreira ED Jr., Bestane WJ, Bartolo EB, Fittipaldi JA. Prevalence and determinants of erectile dysfunction in Santos, southeastern Brazil. Sao Paulo Med J. 2002;120(2):49–54.
- 20 Mak R, De Backer G, Kornitzer M, De Meyer JM. Prevalence and correlates of erectile dysfunction in a population-based study in Belgium. Eur Urol. 2002;41(2):132–8.
- 21 Akkus E, Kadioglu A, Esen A, Doran S, Ergen A, Anafarta K, et al. Prevalence and correlates of erectile dysfunction in Turkey: a population-based study. Eur Urol. 2002;41(3):298–304.
- 22 Nicolosi A, Moreira ED Jr., Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61(1):201–6.
- 23 Bai Q, Xu QQ, Jiang H, Zhang WL, Wang XH, Zhu JC. Prevalence and risk factors of erectile dysfunction in three cities of China: a community-based study. Asian J Androl. 2004; 6(4):343–8.
- 24 Austoni E, Mirone V, Parazzini F, Fasolo CB, Turchi P, Pescatori ES, et al. Smoking as a risk factor for erectile dysfunction: data from the andrology prevention weeks 20012002 a study of the Italian Society of Andrology (s.I.a.). Eur Urol. 2005;48(5):810–8; discussion 8178.
- 25 Cho NH, Ahn CW, Park JY, Ahn TY, Lee HW, Park TS, et al. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabet Med. 2006;23(2):198– 203.
- 26 Millett C, Wen LM, Rissel C, Smith A, Richters J, Grulich A, et al. Smoking and erectile dysfunction: findings from a representative sample of Australian men. Tob Control. 2006; 15(2):136–9.
- 27 Stulhofer A, Bajić Z. Prevalence of erectile and ejaculatory difficulties among men in Croatia. Croat Med J. 2006;47(1):114–24.

Li/Song/Zhang/Zhang

- 28 Hwang TIS, Lo HC, Tsai TF, Chiou HY. Association among hypogonadism, quality of life and erectile dysfunction in middle-aged and aged male in Taiwan. Int J Impot Res. 2007;19(1):69–75.
- 29 Francis ME, Kusek JW, Nyberg LM, Eggers PW. The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J Urol. 2007;178(2): 591–6; discussion 596.
- 30 Asboe D, Catalan J, Mandalia S, Dedes N, Florence E, Schrooten W, et al. Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors. AIDS Care. 2007;19(8):955–65.
- 31 He J, Reynolds K, Chen J, Chen CS, Wu X, Duan X, et al. Cigarette smoking and erectile dysfunction among Chinese men without clinical vascular disease. Am J Epidemiol. 2007;166(7):803–9.
- 32 Kupelian V, Link CL, Rosen RC, McKinlay JB. Socioeconomic status, not race/ethnicity, contributes to variation in the prevalence of erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. J Sex Med. 2008;5(6):1325–33.
- 33 Rhoden EL, Riedner CE, Fornari A, Fuchs SC, Ribeiro EP. Evaluation of the association between lower urinary tract symptoms and erectile dysfunction, considering its multiple risk factors. J Sex Med. 2008;5(11):2662–8.
- 34 Malavige LS, Jayaratne SD, Kathriarachchi ST, Sivayogan S, Fernando DJ, Levy JC. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med. 2008;5(9): 2125–34.
- 35 Chew KK. Alcohol consumption and male erectile dysfunction: an unfounded reputation for risk? J Sex Med. 2009;6(8):2340.
- 36 Lee AC, Ho LM, Yip AW, Fan S, Lam TH. The effect of alcohol drinking on erectile dysfunction in Chinese men. Int J Impot Res. 2010 JulAug;22(4):272–8.
- 37 Stolic RV, Bukumiric ZM. Intima-media thickness of carotid arteries and erectile dysfunction in hemodialysis patients. Hemodial Int. 2010;14(4):510-4.
- 38 Holden CA, McLachlan RI, Pitts M, Cumming R, Wittert G, Ehsani JP, et al. Determinants of male reproductive health disorders: the Men in Australia Telephone Survey (MATeS). BMC Public Health. 2010;10:96.
- 39 Jeong JY, Lee SK, Kang YW, Jang SN, Choi YJ, Kim DH. Relationship between ED and depression among middle-aged and elderly men in Korea: Hallym aging study. Int J Impot Res. 2011 SepOct;23(5):227–34.

- 40 Christensen BS, Grønbaek M, Pedersen BV, Graugaard C, Frisch M. Associations of unhealthy lifestyle factors with sexual inactivity and sexual dysfunctions in Denmark. J Sex Med. 2011;8(7):1903–16.
- 41 Chao JK, Hwang TI, Ma MC, Kuo WH, Liu JH, Chen YP, et al. A survey of obesity and erectile dysfunction of men conscripted into the military in Taiwan. J Sex Med. 2011;8(4): 1156–63.
- 42 Wu C, Zhang H, Gao Y, Tan A, Yang X, Lu Z, et al. The association of smoking and erectile dysfunction: results from the Fangchenggang Area Male Health and Examination Survey (FAM-HES). J Androl. 2012 JanFeb;33(1):59–65.
- 43 Stranne J, Malmsten UG, Areskoug B, Milsom I, Molander U, Peeker R. Influence of age and changes over time on erectile dysfunction: results from two large cross-sectional surveys 11 years apart. Scand J Urol. 2013; 47(3):198–205.
- 44 Olugbenga-Bello AI, Adeoye OA, Adeomi AA, Olajide AO. Prevalence of erectile dysfunction (ED) and its risk factors among adult men in a Nigerian community. Niger Postgrad Med J. 2013;20(2):130–5.
- 45 Costa MR, Reis AM, Pereira BP, Ponciano VC, Oliveira EC. Associated factors and prevalence of erectile dysfunction in hemodialysis patients. Int Braz J Urol. 2014 JanFeb;40(1): 44–55.
- 46 Benli E, Çırakoglu A, Ögreden E, Demir S, Kaya Y, Ibas M, et al. Are erectile functions affected by AB0 blood group? Arch Ital Urol Androl. 2016;88(4):270–3.
- 47 Costa MR, Ponciano VC, Costa TR, de Oliveira AM, Gomes CP, de Oliveira EC. Prevalence and factors associated with erectile dysfunction in patients with chronic kidney disease on conservative treatment. Int J Impot Res. 2017;29(6):219–24.
- 48 Van Vo T, Hoang HD, Thanh Nguyen NP. Prevalence and associated factors of erectile dysfunction among married men in Vietnam. Front Public Health. 2017;5:94.
- 49 Clemente J, Diehl A, Santana PROH, da Silva CJ, Pillon SC, Mari JJ. Erectile dysfunction symptoms in polydrug dependents seeking treatment. Subst Use Misuse. 2017;52(12): 1565-74.
- 50 Seid A, Gerensea H, Tarko S, Zenebe Y, Mezemir R. Prevalence and determinants of erectile dysfunction among diabetic patients attending in hospitals of central and northwestern zone of Tigray, northern Ethiopia: a cross-sectional study. BMC Endocr Disord. 2017;17(1):16.

- 51 Boeri L, Capogrosso P, Pederzoli F, Ventimiglia E, Frego N, Chierigo F, et al. Unrecognized prediabetes is highly prevalent in men with erectile dysfunction-results from a crosssectional study. J Sex Med. 2018;15(8):1117– 24.
- 52 Sanches BC, Laranja WW, Alonso JC, Rejowski RF, Simões FA, Reis LO. Does underestimated penile size impact erectile function in healthy men? Int J Impot Res. 2018;30(4): 158–62.
- 53 Pozzi E, Capogrosso P, Chierigo F, Pederzoli F, Ventimiglia E, Boeri L, et al. Clinical profile of young patients with erectile dysfunction: preliminary findings of a real-life cross-sectional study. Eur Urol Focus. 2018;6(1):1849.
- 54 Shiri R, Koskimäki J, Hakama M, Häkkinen J, Huhtala H, Tammela TL, et al. Effect of lifestyle factors on incidence of erectile dysfunction. Int J Impot Res. 2004;16(5):389–94.
- 55 Araujo AB, Travison TG, Ganz P, Chiu GR, Kupelian V, Rosen RC, et al. Erectile dysfunction and mortality. J Sex Med. 2009;6(9): 2445–54.
- 56 Polsky JY, Aronson KJ, Heaton JP, Adams MA. Smoking and other lifestyle factors in relation to erectile dysfunction. BJU Int. 2005; 96(9):1355–9.
- 57 Song WH, Park J, Yoo S, Oh S, Cho SY, Cho MC, et al. Changes in the prevalence and risk factors of erectile dysfunction during a decade: the Korean internet sexuality survey (KISS), a 10-year-interval web-based survey. World J Mens Health. 2019;37(2):199–209.
- 58 Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. J Psychoactive Drugs. 2001 JulSep;33(3):223–32.
- 59 Cheng JYW, Ng EML, Chen RYL, Ko JSN. Alcohol consumption and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007;19(4):343–52.
- 60 Wang XM, Bai YJ, Yang YB, Li JH, Tang Y, Han P. Alcohol intake and risk of erectile dysfunction: a dose-response meta-analysis of observational studies. Int J Impot Res. 2018; 30(6):342–51.
- 61 Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.
- 62 Arackal BS, Benegal V. Prevalence of sexual dysfunction in male subjects with alcohol dependence. Indian J Psychiatry. 2007;49(2): 109–12.
- 63 Wang PL, Xiao FT, Gong BC, Liu FN. Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies. Oncotarget. 2017;8(58):99013–23.
- 64 Chao C. Associations between beer, wine, and liquor consumption and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2436–47.